NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to ShareholdersAugust 26, 2025 7:30 AM EDT | Source: NervGen Pharma Corp.Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity with clinically meaningful functional gainsOngoing comprehensive analysis of NVG-291's efficacy profile will support upcoming regulatory di ...